Clinic launch guide
Topical Application and Microneedling
Reviewed by ExaVeyra Sciences editorial team · Updated 16 August 2026
ExaVeyra Sciences is a Miami-based B2B supplier of research-use exosomes and 503A compounded peptides to licensed clinics.
| Question | Answer |
|---|---|
| What this is | How intended use separates a cosmetic from a device, what a cleared microneedling device may claim, and how to keep protocol and consent consistent. |
| Who can buy | Licensed clinics and practitioners, after ExaVeyra verifies an active professional license and NPI and, for exosome material, a signed research-use acknowledgment. |
| What ships or is provided | Research-use exosome formats, 503A compounded peptides prepared to prescription by our 503A pharmacy partner, and PRP devices, through one verified account. A certificate of analysis is issued for every lot and provided on request. |
Topical application to intact skin and microneedling are both routine, well-understood procedures with clear regulatory homes. What decides which rules apply is intended use, and intended use is something a practice writes down rather than something inherent in a bottle or a handpiece. That is good news for a clinic building a service line, because it means the analysis is under your control and the record can be made to match the practice from day one.
This page sets out the two lines that matter. First, what makes a topical product a cosmetic and what moves it into the drug frame. Second, what an FDA-cleared microneedling device is cleared to do, quoted from FDA directly, which turns out to be the point most practitioners have never been told.
The cosmetic line
A cosmetic is defined by what it is intended to do. Under the Federal Food, Drug, and Cosmetic Act, articles intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance are cosmetics. Articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, are drugs. A single product can be both, and FDA determines intended use from labeling, marketing, consumer perception and ingredients rather than from a label statement alone.
For a clinic, the practical version is short. Describing a service in terms of how skin looks keeps it in the appearance frame. Describing it in terms of treating a condition moves it into the drug frame, and once there the product needs an approval or an investigational pathway. Nothing about the vial changes; the description does.
Cosmetics also now carry federal obligations. Under the Modernization of Cosmetics Regulation Act of 2022, the responsible person must list each marketed cosmetic product with FDA and manufacturers and processors must register their facilities. Those duties sit with the manufacturer and the responsible person rather than with a clinic applying the product, which is worth knowing when a supplier is asked to evidence its own compliance.
The device line
Microneedling devices for aesthetic use are class II devices under 21 CFR 878.4430, subject to premarket notification under section 510(k) and to special controls. FDA has granted marketing authorization for a limited number of these devices, and the authorized uses are specific: improving the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older. The De Novo and 510(k) databases carry the summary document for each authorized device, and each summary names the areas of the face and body it covers. Product code QAI is the search term.
Not every microneedling product is a device at all. FDA states that products which do not penetrate into the living skin layers, meaning the epidermis and dermis, and which claim only the following, would generally not be devices:
- Facilitate exfoliation of the skin, that is, disruption or removal of the stratum corneum
- Improve the appearance of skin
- Give skin a smoother look and feel
- Give skin a luminous look
So there is a genuine cosmetic tier and a genuine device tier, separated by depth of penetration and by the claims made. A practice choosing equipment is choosing which tier it is operating in.
What a clearance covers, and what it does not
This is the part worth reading twice, and FDA states it plainly on its own microneedling devices page: "Microneedling devices are not approved for delivery of cosmetics, topical medications (for example, creams, ointments, gels), vitamin solutions, drugs, or blood products (for example, platelet-rich plasma (PRP)) into the skin."
That does not make a topical product applied around a procedure unlawful in itself. It means the delivery claim is the thing under scrutiny, not the pairing. A practice that describes its service as microneedling, performed with a cleared device for a cleared indication, and separately applies a topical product to the skin, is describing two things FDA has addressed. A practice that markets the combination as a delivery system is describing an intended use no clearance covers.
FDA also states that re-use of a needle cartridge is unsafe and is not consistent with its review and authorization, even if the cartridge is cleaned. Single-use per patient and per session belongs in the standard operating procedure rather than in a training conversation.
The three sequences, side by side
| Sequence | Frame it sits in | What the record needs to show |
|---|---|---|
| Topical product applied to intact skin | Cosmetic, if the claims are about appearance | Appearance claims only; supplier’s MoCRA listing on file |
| Microneedling with a cleared device, for a cleared indication | Class II device, used within its authorization | Device, indication and treatment area match the clearance summary; single-use cartridge |
| A topical product marketed as delivered by the device | A delivery claim, outside the device classification | This is the claim to reconsider, because no clearance supports it |
Most practices are already operating in the first two rows and only need their written materials to say so. The work is editorial rather than clinical.
A current note on RF microneedling
On 15 October 2025 FDA issued a safety communication on potential risks with certain uses of radiofrequency microneedling devices, which deliver RF energy through an array of microneedles to produce local heating. FDA reported adverse events including burns, scarring, fat loss, disfigurement and nerve damage in dermatologic and aesthetic procedures, stated that its evaluation is ongoing, and asked providers and patients to report complications. It also stated that RF microneedling is a medical procedure rather than a cosmetic treatment and that these devices should not be used at home.
For a practice adding or expanding this equipment, the actionable parts are straightforward. Confirm the specific device authorization and the treatment areas it covers, make sure whoever operates it has documented training on that device, and put MedWatch reporting into the adverse-event procedure so a complication is reported rather than only recorded internally.
Making the record coherent
Three documents decide how a service reads: the written protocol, the informed consent, and the public marketing copy. When all three describe the same intended use in the same terms, the analysis above resolves cleanly and stays resolved. When the marketing reaches further than the protocol, the marketing is the document to bring back into line, because it is the one a reader outside the practice will see first.
A practical review cadence: read the three documents together whenever a device is added, a product line changes, or the website is redesigned. Those are the three moments the language actually drifts.
Sources
- FDA, Microneedling Devices (accessed 16 August 2026)
- FDA, Regulatory Considerations for Microneedling Products: Guidance for Industry and FDA Staff (docket FDA-2017-D-4792) (accessed 16 August 2026)
- FDA, Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling: FDA Safety Communication (15 October 2025) (accessed 16 August 2026)
- 21 CFR 878.4430, Microneedling device for aesthetic use (accessed 16 August 2026)
- FDA, 510(k) Premarket Notification database (accessed 16 August 2026)
- FDA, De Novo Classification database (accessed 16 August 2026)
- FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (accessed 16 August 2026)
- FDA, Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (accessed 16 August 2026)
- FDA, MedWatch Adverse Event Reporting Program (accessed 16 August 2026)
Scientific literature
Each source carries the kind of study it was and, where the study enrolled people, how many. Study design decides what a result can establish, so it is stated rather than left to be inferred. Each line also says what that source is carrying on this page.
- Bailey AJM, et al. Microneedling as an adjuvant to topical therapies for melasma: a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022. doi:10.1016/j.jaad.2021.03.116 PMID:33857549Meta-analysis459 participantsSource 1 supports: Pooled human evidence on microneedling used as an adjuvant to a topical agent, across twelve studies and seven countries. The closest published analogue to the pairing question this page addresses.
- Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. Journal of the American Academy of Dermatology, 2016. doi:10.1016/j.jaad.2015.09.024 PMID:26549251Narrative reviewSource 2 supports: Reviews microneedling use across skin phototypes, cited because the authorised indications are silent on phototype and a practitioner still has to decide.
- Steeb T, et al. Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: results from a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2020. doi:10.1016/j.jaad.2019.09.037 PMID:31928689Meta-analysisSource 3 supports: Pooled analysis of microneedling assisting delivery of a topical agent in a licensed indication, cited as the contrast case to an unapproved pairing. Published as a research letter, so no pooled participant total is reported.